Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants.
JAMA. 2020 Dec 8;324(22):2324-2327. doi: 10.1001/jama.2020.19395.
JAMA. 2020.
PMID: 33289818
Free PMC article.
Clinical Trial.